The American Diabetes Association 2020 Standards of Care for the treatment of hyperglycemia in type 2 diabetes includes a treatment pathway when "cost is a major issue." This pathway recommends use of 2 generic drug classes, thereby codifying differential treatment for those with financial hardship. (1) Does concern that financial hardship warrants differing care impact overall quality of care and patient-clinician relationships? (2) Is this practice ethical?